Loading…
Genotoxicity assessment of atrazine in the Big Blue® Rat2 lacI transgenic cell line
Atrazine, one of the herbicide, is classified as a possible human carcinogen that may cause breast and ovarian cancers. The mutagenic and genotoxic properties of atrazine have been studied using a variety of assays in the past but the results were contradictory. This fact indicates that a more compr...
Saved in:
Published in: | Toxicology and environmental health sciences 2012-09, Vol.4 (3), p.161-166 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Atrazine, one of the herbicide, is classified as a possible human carcinogen that may cause breast and ovarian cancers. The mutagenic and genotoxic properties of atrazine have been studied using a variety of assays in the past but the results were contradictory. This fact indicates that a more comprehensive assessment of the potential genotoxicity of atrazine is needed. For this reasons, we investigated the mutant frequency on
lacI
gene and induction of binucleated micronuclei formation by atrazine
in vitro
using the Big Blue® Rat2
lacI
transgenic fibroblasts, which are transfected by a lambda shuttle vector. These assays carried out at the concentrations of 261.7, 130.8 and 65.4 μg/mL of atrazine, the highest concentration giving 80% survival. These two endpoints were used to compare the induction of point mutations with cytogenetic damages by atrazine under same exposure condition. No significant changes of mutant frequency and binucleated micronuclei frequency induced by atrazine were observed both in the transgenic mutagenesis assay and cytokinesis blocking assay in the absence of metabolic activation system using the Big Blue® Rat2
lacI
transgenic fibroblasts. These results suggest that atrazine did not induce mutation and cytogenetic damage in this experimental system. |
---|---|
ISSN: | 2005-9752 2233-7784 |
DOI: | 10.1007/s13530-012-0131-8 |